

First Trust NYSE Arca Biotechnology UCITS ETF

The Fund is a passively managed index-tracking fund that seeks to provide investors with investment results that correspond generally to the price and yield of the NYSE Arca Biotechnology IndexSM, (the "Index"), before fees and expenses. The modified equally-weighted index is designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Performance

Past performance does not predict future returns

Performance Since Inception (%)



Performance Summary (%)	1 M	3 M	YTD	1 Y	3 Y	5 Y	Since Inception
Acc USD	3.02	-0.05	-2.70	0.75	-3.86	-	-1.55
Tracking Index	3.07	0.10	-2.34	1.36	-3.42	-	-1.08

Performance for periods under one year is cumulative and over one year is annualised.

12-Month Performance Periods (%)	30.06.19	30.06.20	30.06.21	30.06.22	30.06.23	30.06.24
Acc USD	-	2.88	-21.55	12.44	0.75	-
Tracking Index	-	3.48	-21.44	13.13	1.36	-

Fund performance is the performance of the share class since its inception, shown net of fees including re-invested dividends in the base currency of the share class which is in USD. Performance can go up as well as down, and investors may lose some or all of their capital. Returns may increase or decrease as a result of currency and exchange rate fluctuations. Please refer to the 'Risks' section on Page 3 for more details on risks associated with an investment in the fund.

FBT	Acc USD
ISIN	IE00BL0L0H60
Asset Class	Equity
Fund Inception	27.05.2020
Share Class Inception	27.05.2020
Total Expense Ratio	0.60%
Base Currency	USD
Income Treatment	Accumulating
Total Fund AUM	\$4.69 million
Outstanding Shares	250,002
UCITS Compliant	Yes
Domicile	Ireland
Investment Manager	First Trust Advisors
Rebalance Frequency	Quarterly
Replication Method	Physical - Full Replication
SFDR Classification	Article 6
Tracking Index	NYSE® Arca Biotechnology Index

Trading Information

Exchange	Ccy	Ticker	SEDOL
London Stock Exchange	GBP	FBT LN	BLBPQX5
London Stock Exchange	USD	FBTU LN	BJYFRJ1
Borsa Italiana	EUR	FBT IM	BLCWGQ8

ISA
 SIPP
 UK Reporting Status

CONTACT US

+353 (0)1 913 1339

info@ftgportfolios.com

Fitzwilliam Hall, Dublin 2, D02 T292

www.ftglobalportfolios.com

Portfolio

TOP 10 HOLDINGS (%)

Alnylam Pharmaceuticals, Inc.	5.19
Corcept Therapeutics Incorporated	4.39
United Therapeutics Corporation	4.36
Halozyme Therapeutics, Inc.	4.31
Vertex Pharmaceuticals Incorporated	3.75
Amgen Inc.	3.72
Biogen Inc.	3.72
Regeneron Pharmaceuticals, Inc.	3.66
Natera, Inc.	3.64
argenx SE (ADR)	3.60

Top 10 Holdings as % of Total



Top 10 holdings as a percentage of Total Net Assets. Portfolio Holdings are subject to change at any time. References to specific securities should not be construed as a recommendation to buy or sell and should not be assumed profitable.

SECTOR ALLOCATION (%)

Health Care	100.00	
-------------	--------	--

COUNTRY ALLOCATION (%)

United States	80.86
The Netherlands	3.61
Switzerland	3.52
Cayman Islands	3.20
Ireland	3.13
Germany	2.95
Denmark	2.73

FUND CHARACTERISTICS

Max Market Cap	\$167.6bn
Median Market Cap	\$14.6bn
Min Market Cap	\$1.8bn
Price/Earnings	26.23
Price/Book	3.82
Price/Cash Flow	22.43
Price/Sales	5.57
Index Yield	0.27%

- The index is reconstituted and rebalanced quarterly in January, April, July and October.
- The securities selected for inclusion in the index are equally weighted. Index composition changes during scheduled reconstitutions are also subject to certain buffers designed to limit turnover
- The highest ranked 30 securities are selected for inclusion in the index.
 - Additionally, the total number of index constituents classified to the Biotech Tools & Diagnostics sub-industry is capped at 6 constituents. If the limit is reached, the lowest ranked Biotech Tools & Diagnostics constituents are replaced with the next highest ranked Biotech Therapeutics non-constituents until this rule is met.
- Eligible securities are then ranked in descending order based on the following factors. These three distinct ranks are then combined to yield one comprehensive rank based on their respective weights:
 - 50%: Net sales (revenue) over the last 12 months,
 - 25%: Ratio of net sales (revenue) to R&D (research and development) expenditures over the last 12 months,
 - 25%: Percentage change in R&D expenditures (over the last 12 months) from those three years prior.
- To be included in the index, a common stock or depositary receipt must be listed on a qualifying U.S. securities exchange, and meet the size and liquidity standards of the index
- The Biotechnology sub-industry group includes:
 - The Biotech Therapeutics Sub-Industry: Companies engaged in the research and development of therapeutic treatments (including companies in the trial phase of therapeutic development), but are not focused on the commercialisation and mass production of pharmaceutical drugs,
 - The Biotech Tools & Diagnostics Sub-Industry: Companies engaged in the production and provisioning of tools, systems or processes that enable biotechnology practices (including companies that provide assaying equipment, sequencing techniques or systems, DNA processing, or cellular processing).
- The NYSE® Arca® Biotechnology Index is an equal dollar-weighted index designed to measure the performance of 30 leading biotechnology companies classified within the Biotechnology sub-industry group of the ICE Uniform Sector Classification schema.

Risks

- **The Fund may not achieve its investment objective and the value of shares in the Fund may fall.**
- Neither First Trust Global Portfolios Management Limited ("FTGPM") nor any of its affiliates, guarantees the performance or the future returns of the Fund.
- The Fund invests in biotechnology and pharmaceutical companies, which are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.
- There is no assurance that the Index will continue to be calculated and published on the basis described in the Prospectus. In addition, the Fund's return may not match the return of the Index.
- See also the description of the risks applicable to the Fund in "Risk Factors" in the Prospectus.

Important Information

This marketing communication is issued by First Trust Global Portfolios Management Limited ("FTGPM") whose place of business is Fitzwilliam Hall, Fitzwilliam Place, Dublin 2, D02 T292. FTGPM is authorised and regulated by the Central Bank of Ireland ("CBI") (C185737). The Fund is also regulated by the CBI.

Nothing contained herein constitutes investment, legal, tax or other advice and it is not to be solely relied on in making an investment or other decision, nor does the document implicitly or explicitly recommend or suggest an investment strategy, reach conclusions in relation to an investment strategy for the reader, or provide any opinions as to the present or future value or price of any fund. It is not an invitation, offer, or solicitation to engage in any investment activity, including making an investment in the Fund, nor does the information, recommendations or opinions expressed herein constitute an offer for sale of the Fund.

The Fund is an open-ended sub-fund of First Trust Global Funds PLC (the "Company"), an umbrella UCITS fund with segregated liability between sub-funds, incorporated with limited liability as an investment company with variable capital under the laws of Ireland with UCITS registered number 514357.

The material in this marketing communication is not comprehensive and must therefore be read in conjunction with the Fund's prospectus and the key information document ("KID") which contains material information not contained herein, including the terms of investment and information regarding investment risks and restrictions, fees and expenses and conflicts of interests. Potential investors should pay particular attention to the risk disclosures in the "Risk Factors" section of the Fund's prospectus (available in English) and KIDs (available for each share class of each of the sub-funds of the Company and in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the UCITS Directive)). No assurance can be given that the Fund's investment objective will be achieved or that the Fund will generate a positive return. Please contact FTGPM or visit www.ftglobalportfolios.com to obtain a prospectus and/

or KIDs. Investors and potential investors can obtain a summary in English of investor rights and information on access to collective redress mechanisms in the event of litigation at the following website: https://www.ftglobalportfolios.com/Content/SUMMARY_OF_INVESTOR_RIGHTS.

The Fund is currently notified for marketing into a number of EU Member States under the UCITS Directive. The Company may however decide to terminate the arrangements made for the marketing of any share class of the Fund at any time using the process contained in the UCITS Directive.

Any UCITS ETF's units / shares purchased on the secondary market cannot usually be sold directly back to UCITS ETF. Investors must buy and sell units / shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units / shares and may receive less than the current net asset value when selling them.

The Company's portfolio holdings policy is designed to be transparent, whilst being in the best interest of the Fund and protecting the confidentiality of each Fund's portfolio holdings. The full portfolio holdings for the Fund shall generally be available daily, with a one-day lag, on www.ftglobalportfolios.com. Any portfolio holdings information which may otherwise be provided on request shall be provided on a confidential basis.

NYSE and NYSE® Arca Biotechnology Index are service/trademarks of ICE Data Indices, LLC or its affiliates ("IDI") and have been licensed for use by First Trust in connection with the Fund. The Fund is not sponsored, endorsed, sold or promoted by IDI and IDI makes no representations or warranties regarding the advisability of investing in the Fund or as to the result to be obtained by any person from use of the Index in connection with the trading of the Fund. IDI and its third party suppliers accept no liability in connection with use of the index or the Fund. See the prospectus for a full copy of the disclaimer.

For Investors in Belgium

The offering of Shares has not been and will not be notified to the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten/Autorité des Services et Marchés Financiers) nor has this document been, nor will it be, approved by the Financial Services and Markets Authority. Shares may be offered in Belgium only to professional investors, in reliance of article 5, §1 of the Law of August 3, 2012 on collective investment undertakings that satisfy the conditions of Directive 2009/65/EC and undertakings for investments in receivables (the "Law of August 3, 2012"), such investors acting for their own account and subject to them complying with the resale condition as set forth in that article 5, §1 of the Law of August 3, 2012.

For Investors in Denmark

This document is only for the attention of "Professional" investors as defined in Directive 2004/39/EC dated 21 April 2004 on Markets in Financial Instruments (MIFID), to investment services providers and any other professional of the financial industry. The products and services to which this communication relates are only available to such persons and persons of any other description should not rely on this communication. The Fund has been registered with the Financial Supervisory Authority of Denmark (Finanstilsynet) in order to market its shares for sale to professional investors only in Denmark in accordance with the Danish Investment Associations Act and Executive Order on the Marketing of Foreign UCITS in Denmark, each as amended from time to time.

For Investors in Finland

This document is only for the attention of "Professional" investors as defined in Finnish law implementing Directive 2004/39/EC dated 21 April 2004 on Markets in Financial Instruments (MIFID), to investment services providers and any other professional of the financial industry. The products and services to which this communication relates are only available to such persons and persons of any other description should not rely on this communication. The Fund has been registered with the Financial Supervisory Authority of Finland (Finanssivalvonta) in order to market its shares for sale to professional investors only in Finland in accordance with the Finnish Act on Common Funds (48/1999) as amended from time to time.

For Investors in Luxembourg

The Fund is registered for public offer in Luxembourg. The Prospectus, Key Information Document ("KID") and other documents as well as the annual and semi-annual reports are available in English free of charge from CACEIS Bank Luxembourg, 5, allée Scheffer, L-2520 Luxembourg.

For Investors in Monaco

The Fund may not be offered or sold, directly or indirectly, to the public in Monaco other than by a Monaco Bank or a duly authorized Monegasque intermediary acting as a professional institutional investor which has such knowledge and experience in financial and business matters as to be capable of evaluating the risks and merits of an investment in the Fund. Consequently, this document may only be communicated to (i) banks, and (ii) portfolio management companies duly licensed by the "Commission de Contrôle des Activités Financières" by virtue of Law n° 1.338, of September 7, 2007, and authorized under Law n° 1.144 of July 26, 1991. Such regulated intermediaries may in turn communicate this document to potential investors under their own liability.

For Investors in the Netherlands

This document is only for the attention of "Professional" investors as defined in Directive 2004/39/EC dated 21 April 2004 on Markets in Financial Instruments ("MIFID"), to investment services providers and any other professional of the financial industry. The products and services to which this communication relates are only available to such persons and persons of any other description should not rely on this communication. The Company has completed its notification to the Authority Financial Markets (Stichting Autoriteit Financiële Markten) in the Netherlands in order to market its shares for sale to the public in the Netherlands according to Section 2:72 of the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht) as amended from time to time.

For Investors in Sweden

This document is only for the attention of "Professional" investors as defined in the Swedish Securities Markets Act (Sw. lag (2007:528) om värdepappersmarknaden), implementing Directive 2004/39/EC dated 21 April 2004 on Markets in Financial Instruments (MIFID) into Swedish law, to investment services providers and any other professional of the financial industry. The products and services to which this communication relates are only available to such persons and persons of any other description should not rely on this communication. The Fund has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) in accordance with Chapter 1, Section 7 of the Swedish Securities Funds Act (Sw. lag (2004:46) om värdepappersfonder), as amended from time to time. Prospective investors may obtain the KID in Swedish and the current Prospectus, the articles of incorporation, as well as the latest annual and semi-annual report, in English, free of charge from www.ftgportfolios.com.

For Investors in Switzerland

The distribution of shares in Switzerland will be exclusively made to, and directed at, qualified investors (the "Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended ("CISA") and its implementing ordinance. Accordingly, the Fund has not been and will not be registered with the Swiss Financial Market Supervisory Authority (FINMA). This document and/or any other offering materials relating to the Fund may be made available in Switzerland solely to Qualified Investors. For this, the Fund has appointed as Swiss Representative Waystone Fund Services (Switzerland) SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: switzerland@waystone.com. The Fund's paying agent is Banque Cantonale de Genève. Any Fund Documentation may be obtained free of charge from the Swiss Representative in Lausanne. The information provided here is for general information only and historical performance is not a guide to current or future performance.